RU2020110366A - Новые соединения сульфонамидкарбоксамидов - Google Patents

Новые соединения сульфонамидкарбоксамидов Download PDF

Info

Publication number
RU2020110366A
RU2020110366A RU2020110366A RU2020110366A RU2020110366A RU 2020110366 A RU2020110366 A RU 2020110366A RU 2020110366 A RU2020110366 A RU 2020110366A RU 2020110366 A RU2020110366 A RU 2020110366A RU 2020110366 A RU2020110366 A RU 2020110366A
Authority
RU
Russia
Prior art keywords
disease
group
optionally
substituted
paragraphs
Prior art date
Application number
RU2020110366A
Other languages
English (en)
Other versions
RU2020110366A3 (ru
Inventor
Мэтью КУПЕР
Дэвид Миллер
Ангус МАКЛАУД
ВИЛТЕНБУРГ Джимми ВАН
Стивен Том
Стивен СТ-ГАЛЛАЙ
Джонатан ШЭННОН
Томас ЭЙЛАНИН
Стюарт ОНЬОНЗ
Иэн СТРАТ
Original Assignee
Инфлазоум Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713082.4A external-priority patent/GB201713082D0/en
Priority claimed from GBGB1718563.8A external-priority patent/GB201718563D0/en
Priority claimed from GBGB1721726.6A external-priority patent/GB201721726D0/en
Priority claimed from GBGB1810983.5A external-priority patent/GB201810983D0/en
Application filed by Инфлазоум Лимитед filed Critical Инфлазоум Лимитед
Publication of RU2020110366A publication Critical patent/RU2020110366A/ru
Publication of RU2020110366A3 publication Critical patent/RU2020110366A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52Y being a hetero atom
    • C07C311/54Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/55Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Claims (83)

1. Соединение формулы I:
Figure 00000001
,
где Q выбирают из О или S;
R1 представляет собой насыщенную или ненасыщенную гидрокарбильную группу, причем данная гидрокарбильная группа может быть с нормальной или разветвленной цепью, или представляет собой или включает циклические группы, причем гидрокарбильная группа может быть необязательно замещенной, и при том, что гидрокарбильная группа может необязательно содержать один или более гетероатомов N, О или S в своем углеродном скелете; и
R2 представляет собой циклическую группу, замещенную в α-положении одновалентной гетероциклической группой или одновалентной ароматической группой, причем кольцевой атом гетероциклической или ароматической группы непосредственно присоединен к кольцевому атому циклической группы, при этом гетероциклическая или ароматическая группа необязательно может быть замещена, и при том, что циклическая группа необязательно может быть дополнительно замещена.
2. Соединение по п. 1, где R1 представляет собой 4-10-членную циклическую группу, причем данная циклическая группа может необязательно быть замещена.
3. Соединение по п. 1, где R1 представляет собой С115 алкильную, С215 алкенильную или С215 алкинильную группу, все из которых могут необязательно быть замещены, и все из которых могут необязательно содержать один, два или три гетероатома N, О или S в своем углеродном скелете.
4. Соединение по любому одному из пп. 1-3, где R1 замещена одним, двумя или тремя заместителями, независимо выбранными из галогена; -CN; -N3; -Rβ; -ОН; -ORβ; -SO2Rβ; -NH2; -NHRβ; -N(Rβ)2; -Rα-NH2; -Rα-NHRβ; -Rα-N(Rβ)2; -CORβ; -COORβ; -OCORβ; -Rα-CORβ; -Rα-COORβ; -Rα-OCORβ; -CONH2; -CONHRβ; -CON(Rβ)2; или оксо (=O);
где каждую -Rα- независимо выбирают из C1-C6 алкиленовой группы, причем один или два атома углерода в скелете алкиленовой группы могут необязательно быть заменены одним или двумя гетероатомами N, О или S, и при этом данная алкиленовая группа может необязательно быть замещена одним или двумя галогенами и/или группами -Rβ; и
где каждую -Rβ независимо выбирают из С16 алкильной, С26 алкенильной, С26 алкинильной или С26 циклической группой, причем, любая -Rβ может необязательно быть замещена одной, двумя или тремя С14 алкильными, С14 галогеналкильными, С37 циклоалкильными, -O(C1-C4 алкильными), -O(C1-C4 галогеналкильными), -O(С37 циклоалкильными), галогенами, -ОН, -NH2, -CN, -С=СН или оксо (=O) группами.
5. Соединение по любому одному из пп. 1-4, где α-замещенная циклическая группа R2 представляет собой 5- или 6-членную циклическую группу, причем данная циклическая группа может необязательно быть дополнительно замещена.
6. Соединение по любому одному из пп. 1-5, где одновалентная гетероциклическая или ароматическая группа в α-положении данной циклической группы R2 представляет собой фенильную или 5- или 6-членную гетероциклическую группу, все из которых могут необязательно быть замещены.
7. Соединение по любому одному из пп. 1-6, где одновалентная гетероциклическая или ароматическая группа в α-положении данной циклической группы R2 представляет собой фенил, пиридинил, пиримидинил или пиразолил, все из которых могут необязательно быть замещены одним или двумя заместителями, независимо выбранными из галогена, -ОН, -NH2, -CN, С13 алкильной или -O(С13 алкильной) групп.
8. Соединение по любому одному из пп. 1-7, где циклическая группа R2 дополнительно замещена одним или двумя заместителями, независимо выбранными из галогена, -Rδ, -ORδ или -CORδ групп, причем каждую Rδ независимо выбирают из C1-C6 алкильной, С26 алкенильной, С26 алкинильной или С26 циклической группы, и при этом каждая Rδ необязательно дополнительно замещена одной или более группами галогенов.
9. Соединение по любому одному из пп. 1-8, где Q представляет собой О.
10. Соединение, выбранное из группы, состоящей из:
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
11. Фармацевтически приемлемая соль, сольват или пролекарство соединения по любому одному из пп. 1-10.
12. Фармацевтическая композиция, содержащая соединение по любому одному из пп. 1-10, или фармацевтически приемлемую соль, сольват или пролекарство по п. 11, и фармацевтически приемлемый эксципиент.
13. Фармацевтическая композиция по п. 12, отличающаяся тем, что данная фармацевтическая композиция представляет собой фармацевтическую композицию для местного применения.
14. Соединение по любому одному из пп. 1-10 или фармацевтически приемлемая соль, сольват или пролекарство по п. 11, или фармацевтическая композиция по п. 12 или 13 для применения в медицине.
15. Соединение, фармацевтически приемлемая соль, сольват, пролекарство или фармацевтическая композиция по п. 14 для применения в лечении или предотвращении заболевания, расстройства или патологического состояния, причем заболевание, расстройство или патологическое состояние отвечает на ингибирование NLRP3.
16. Соединение, фармацевтически приемлемая соль, сольват, пролекарство или фармацевтическая композиция по п. 14 или 15 для применения в лечении или предотвращении заболевания, расстройства или патологического состояния, причем заболевание, расстройство или патологическое состояние выбирают из:
(i) воспаления;
(ii) аутоиммунного заболевания;
(iii) рака;
(iv) инфекции;
(v) заболевания центральной нервной системы;
(vi) метаболического заболевания;
(vii) сердечно-сосудистого заболевания;
(viii) респираторного заболевания;
(ix) заболевания печени;
(x) заболевания почек;
(xi) глазного заболевания;
(xii) заболевания кожи;
(xiii) лимфатического заболевания;
(xiv) психологического расстройства;
(xv) болезни трансплантат против хозяина;
(xvi) аллодинии; а также
(xvii) любого заболевания, при котором у человека определено наличие зародышевой или соматической немолчащей мутации в NLRP3.
17. Соединение, фармацевтически приемлемая соль, сольват, пролекарство или фармацевтическая композиция по п. 14 или 15 для применения в лечении или предотвращении заболевания, расстройства или патологического состояния, причем заболевание, расстройство или патологическое состояние выбирают из:
(i) криопирин-ассоциированных периодических синдромов (CAPS);
(ii) синдрома Макла-Уэлльса (MWS);
(iii) семейного холодового аутовоспалительного синдрома (FCAS);
(iv) много системно го воспалительного заболевания новорожденных (NOMID);
(v) семейной средиземноморской лихорадки (FMF);
(vi) пиогенного артрита, синдрома гангренозной пиодермы и угрей (PAPA);
(vii) гипериммуноглобулинемии D и синдрома периодической лихорадки (HIDS);
(viii) периодического синдрома, связанного с рецептором фактора некроза опухоли (TNF) (TRAPS);
(ix) системного ювенильного идиопатического артрита;
(x) болезни Стилла у взрослых (AOSD);
(xi) рецидивирующего полихондрита;
(xii) синдрома Шницлера;
(xiii) синдрома Свита;
(xiv) болезни Бехчета;
(xv) антисинтетазного синдрома;
(xvi) дефицита антагониста рецептора интерлейкина 1 (DIRA); а также
(xvii) гаплонедостаточности А20 (НА20).
18. Способ ингибирования NLRP3, включающий применение соединения по любому одному из пп. 1-10 или фармацевтически приемлемой соли, сольвата или пролекарства по п. 11, или фармацевтической композиции по п. 12 или 13 для ингибирования NLRP3.
RU2020110366A 2017-08-15 2018-08-15 Новые соединения сульфонамидкарбоксамидов RU2020110366A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1713082.4 2017-08-15
GBGB1713082.4A GB201713082D0 (en) 2017-08-15 2017-08-15 Novel compounds
GB1718563.8 2017-11-09
GBGB1718563.8A GB201718563D0 (en) 2017-11-09 2017-11-09 Novel compounds
GB1721726.6 2017-12-22
GBGB1721726.6A GB201721726D0 (en) 2017-12-22 2017-12-22 Novel compounds
GB1810983.5 2018-07-04
GBGB1810983.5A GB201810983D0 (en) 2018-07-04 2018-07-04 Novel compounds
PCT/EP2018/072111 WO2019034686A1 (en) 2017-08-15 2018-08-15 NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS

Publications (2)

Publication Number Publication Date
RU2020110366A true RU2020110366A (ru) 2021-09-16
RU2020110366A3 RU2020110366A3 (ru) 2022-02-21

Family

ID=63350528

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020110366A RU2020110366A (ru) 2017-08-15 2018-08-15 Новые соединения сульфонамидкарбоксамидов

Country Status (16)

Country Link
US (1) US20200361895A1 (ru)
EP (1) EP3668861A1 (ru)
JP (2) JP2020531435A (ru)
KR (1) KR20200041918A (ru)
CN (1) CN111132974B (ru)
AU (1) AU2018317794A1 (ru)
BR (1) BR112020002948A2 (ru)
CA (1) CA3071143A1 (ru)
IL (1) IL272555A (ru)
MA (1) MA49901A (ru)
MX (1) MX2020001777A (ru)
RU (1) RU2020110366A (ru)
SG (1) SG11202001164SA (ru)
TW (1) TW201910314A (ru)
UY (1) UY37845A (ru)
WO (1) WO2019034686A1 (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739356C2 (ru) 2015-02-16 2020-12-23 Дзе Юниверсити Оф Квинсленд Сульфонилмочевины и родственные соединения и их применение
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
MA47308A (fr) 2017-01-23 2019-11-27 Genentech Inc Composés chimiques comme inhibiteurs de l'activité interleukine-1
WO2018215818A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
JP7235742B2 (ja) 2017-07-07 2023-03-08 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
DE102017118230B4 (de) * 2017-08-10 2021-04-22 Christoph Lucks Verfahren zur Analyse und/oder Überwachung von Brücken sowie entsprechendes System und entsprechende Verwendung
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020110394A (ru) 2017-08-15 2022-01-20 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
KR20200041919A (ko) * 2017-08-15 2020-04-22 인플라좀 리미티드 Nlrp3 저해제로서의 설포닐유레아 및 설포닐티오유레아
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
CR20200588A (es) 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CN112584899A (zh) 2018-07-03 2021-03-30 诺华股份有限公司 Nlrp调节剂
SG11202012159TA (en) 2018-07-20 2021-01-28 Hoffmann La Roche Sulfonylurea compounds as inhibitors of interleukin-1 activity
SG11202013062VA (en) 2018-07-20 2021-02-25 Hoffmann La Roche Sulfonimidamide compounds as inhibitors of interleukin-1 activity
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
JP7682813B2 (ja) * 2019-06-12 2025-05-26 ノッドセラ リミテッド スルホニル尿素誘導体及びその使用
EP3986879B1 (en) 2019-06-21 2024-10-02 AC Immune SA Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
US20220289766A1 (en) 2019-08-16 2022-09-15 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
CN114302876A (zh) 2019-09-06 2022-04-08 英夫拉索姆有限公司 Nlrp3抑制剂
BR112022009209A2 (pt) * 2019-11-12 2022-07-26 Chengdu Baiyu Pharmaceutical Co Ltd Derivado de amida e método de preparação e uso do mesmo na medicina
WO2021111351A1 (en) * 2019-12-03 2021-06-10 Cadila Healthcare Limited Novel substituted sulfonylurea and sulfoximineurea derivatives
JP2023513935A (ja) 2020-02-18 2023-04-04 インフレイゾーム リミテッド 化合物
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク. 線維芽細胞増殖因子受容体キナーゼの阻害剤
CN115768749B (zh) * 2020-06-11 2024-04-19 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物
CA3178361A1 (en) 2020-06-19 2021-12-23 Emanuele Gabellieri Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
US20230348437A1 (en) * 2020-07-02 2023-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
WO2022237782A1 (zh) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 酰胺衍生物及其应用
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
IL308071A (en) * 2021-06-23 2023-12-01 Hoffmann La Roche Process for preparing NLRP3 inhibitors
MX2024003948A (es) * 2021-09-29 2024-06-28 Viva Star Biosciences Suzhou Co Ltd Nuevos compuestos de sulfonilurea sustituidos como inhibidores de la actividad de interleucina-1.
CN115894478B (zh) * 2021-09-30 2025-04-04 杭州民生药物研究院有限公司 一种新型吡啶并吡唑类杂环化合物及其应用
JP2024523690A (ja) * 2021-12-02 2024-06-28 上▲海▼栖臻医▲薬▼科技有限公司 芳香族化合物、その医薬組成物及びその使用
EP4452972A1 (en) 2021-12-22 2024-10-30 AC Immune SA Dihydro-oxazol derivative compounds
CN118871426A (zh) * 2022-02-15 2024-10-29 豪夫迈·罗氏有限公司 用于制备1,2,3,5,6,7-六氢-s-二环戊二烯并苯衍生物的方法
US12338255B2 (en) 2022-02-21 2025-06-24 Viva Star Biosciences (Suzhou) Co., Ltd. Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
US20250283896A1 (en) * 2022-04-25 2025-09-11 Vanderbilt University Probes and methods for targeted visualization of nlrp3 inflammasomes
AU2023307538A1 (en) 2022-07-14 2025-01-23 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
AR130151A1 (es) * 2022-08-10 2024-11-06 Takeda Pharmaceuticals Co Compuesto heterocíclico
WO2024249539A1 (en) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
GB202319256D0 (en) 2023-12-15 2024-01-31 Amphista Therapeutics Ltd Novel compounds for targeted protein degradation
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) * 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
NL129208C (ru) * 1965-07-14
DE4039733A1 (de) * 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
AU2494792A (en) * 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
AU2496492A (en) * 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH06199047A (ja) * 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
WO1997011057A1 (en) * 1995-09-22 1997-03-27 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
WO1997030978A1 (fr) * 1996-02-26 1997-08-28 Sumitomo Pharmaceuticals Company, Limited Derives de sulfonylureidopyrazole
CZ20013248A3 (cs) * 1999-03-15 2002-04-17 Axys Pharmaceuticals, Inc. Nové sloučeniny a prostředky jako inhibitory proteázy
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
BR0209855A (pt) * 2001-05-18 2004-06-15 Solvay Pharm Gmbh Uso de compostos com atividade inibidora de nep/mp combinada na preparação de medicamentos
FI110677B (fi) * 2001-10-12 2003-03-14 Jujo Thermal Oy Lämpöherkkä tallennusmateriaali
DK1441734T3 (da) * 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
ZA200408711B (en) * 2002-05-28 2006-10-25 Dimensional Pharamaceuticals I Novel thiophene amidines, composition thereof, and methods of treating complement-mediated diseases and conditions
WO2006085815A1 (en) * 2005-02-11 2006-08-17 Astrazeneca Ab Thiazole derivatives, their process for their preparation and their use in therapy
EP1874788A1 (en) * 2005-04-19 2008-01-09 Ranbaxy Laboratories Limited Monosaccharide derivatives as anti-inflammatory and/or anti-cancer agents
US8486987B2 (en) * 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
PL221813B1 (pl) * 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania
RU2739356C2 (ru) * 2015-02-16 2020-12-23 Дзе Юниверсити Оф Квинсленд Сульфонилмочевины и родственные соединения и их применение
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US10080741B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
JP7235742B2 (ja) * 2017-07-07 2023-03-08 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
EP3668843A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
KR20200041919A (ko) * 2017-08-15 2020-04-22 인플라좀 리미티드 Nlrp3 저해제로서의 설포닐유레아 및 설포닐티오유레아
RU2020110394A (ru) * 2017-08-15 2022-01-20 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
US11542255B2 (en) * 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668840A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds

Also Published As

Publication number Publication date
AU2018317794A1 (en) 2020-02-13
TW201910314A (zh) 2019-03-16
US20200361895A1 (en) 2020-11-19
UY37845A (es) 2020-06-30
CA3071143A1 (en) 2019-02-21
JP2023055855A (ja) 2023-04-18
BR112020002948A2 (pt) 2020-08-11
WO2019034686A1 (en) 2019-02-21
MX2020001777A (es) 2020-03-24
KR20200041918A (ko) 2020-04-22
MA49901A (fr) 2020-06-24
EP3668861A1 (en) 2020-06-24
JP2020531435A (ja) 2020-11-05
CN111132974A (zh) 2020-05-08
SG11202001164SA (en) 2020-03-30
RU2020110366A3 (ru) 2022-02-21
IL272555A (en) 2020-03-31
CN111132974B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
RU2020110366A (ru) Новые соединения сульфонамидкарбоксамидов
RU2020115098A (ru) Соединения новых сульфонамидкарбоксамидов
RU2020110394A (ru) Новые соединения сульфонамидкарбоксамидов
RU2020110219A (ru) Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3
HRP20201263T1 (hr) Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida
HRP20220195T1 (hr) Novi spojevi sulfonamid karboksamida
Burger Impact of interleukin-6 in hematological malignancies
Assier et al. Interleukin-6: from identification of the cytokine to development of targeted treatments
Wang et al. Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases
Koenders et al. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis
Tanaka et al. Immunotherapeutic implication of IL-6 blockade
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
WO2019166623A1 (en) Phenylsulfonylurea derivatives useful as nlrp3 inhibitors
RU2015133450A (ru) Соединения имидазопиридина и их применение
RU2018106453A (ru) Соединения
CA2848662A1 (en) Il-12/p40 binding proteins
RU2017134551A (ru) Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
RU2016131189A (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
Bournia et al. Recent advances in the treatment of systemic sclerosis
RU2018142988A (ru) Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена
RU2020137883A (ru) Композиции, содержащие 15-hepe, и способы их применения
JP2021513512A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
RU2021106340A (ru) Новые соединения сульфонамидов мочевины
RU2020134742A (ru) Новые соединения